MAGL Targeted PROTAC Degrader Simultaneously Enhances P53 for Synergistic Treatment of Glioblastoma Stem Cell

Researchers presented a proof-of-concept PROTAC design tailored for glioblastoma (GBM) stem cells, potentially addressing the occurrence challenges for GBM.